September 3, 2022 — ICER – the Institute for Clinical and Economic Review – has released its final report on the effectiveness and value of obesity meds and set a public hearing for September 16. Let’s say it right up front. This private nonprofit is trying to do something that is almost impossibly hard. Making objective sense from the […]
June 28, 2022 — Today we will take every little bit of good news we can. So the word that FDA is adding one more obesity treatment option for teens with Qsymia, though incremental, is certainly good news. In approving the drug for this use, FDA noted that the teens taking it lost between five and seven percent of […]
May 2, 2022 — At the Pediatric Endocrine Society annual meeting this weekend came some good news. Pediatric obesity care providers may soon have one more option for treating teens with obesity. In a well-controlled study of Qsymia for treating obesity in teens, Aaron Kelly reported impressive results. He and his colleagues tested two doses – a mid-range and […]
June 17, 2016 — A new study published this week in JAMA provides useful perspective on the safety and efficacy of the newer obesity meds now available for managing the chronic disease of obesity. Rohan Khera and colleagues integrated the results for 29,018 patients in 28 published clinical trials and concluded: Among overweight or obese adults, orlistat [Alli, Xenical], […]
July 2, 2015 — The response to new data on obesity treatment — published today in the New England Journal of Medicine — gives us some flicker of hope that attitudes about obesity treatment are shifting. The publication is the 56-week pivotal safety and efficacy study of liraglutide for treating obesity. Xavier Pi-Sunyer and colleagues found that most (63%) […]
August 7, 2014 — A superficial analysis of new obesity treatment options in JAMA Internal Medicine has prompted some strong pushback from two of the top organizations devoted to obesity. Leaders of the Obesity Society (TOS) and the Obesity Action Coalition (OAC) this week published rebuttals in the journal to the earlier publication on these new obesity drugs. In the original publication, Steven Woloshin and Lisa […]
